Aligos Therapeutics, Inc.

During the three months ended December 31, 2025, none of our directors or officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended)adopted, terminated ormodified a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

On March 3, 2026, the Company’s Board of Directors adopted resolutions approving the ratification, pursuant to Section 204 of the Delaware General Corporation Law (the "DGCL"), of the issuance of 911 shares of the Company's common stock in excess of the share reserve under the Company's 2020 Employee Stock Purchase Plan

(the “ESPP”). The shares were issued on December 8, 2025 in connection with an offering period that ended in November 2025. The failure of authorization was that such shares were issued in excess of the number of shares available for issuance under the ESPP’s share reserve at the time of issuance. The public filing of this Annual Report on Form 10-K with the Securities and Exchange Commission constitutes the notice required to be given under Section 204(g) of the DGCL. Any claim that any defective corporate act or putative stock ratified pursuant to the ratification is void or voidable due to the failure of authorization, or that the Delaware Court of Chancery should declare in its discretion that the ratification in accordance with Section 204 of the DGCL not be effective or be effective only on certain conditions, must be brought within 120 days from the giving of this notice (which is deemed given on the date that this Annual Report on Form 10-K is filed with the Securities and Exchange Commission).